ArticleAmerican journal of translational research2026
Effects of proton pump inhibitors plus gastroprokinetic agents on laryngopharyngeal reflux disease and factors influencing prognosis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the efficacy of proton pump inhibitors (PPIs) combined with gastroprokinetic agents for laryngopharyngeal reflux disease (LPRD) and to explore factors associated with prognosis.
methodsA retrospective analysis was performed in 120 patients with LPRD treated at our institution from January 2023 to December 2024. They were classified into a combination group (n=60, PPI plus gastroprokinetic agents) and a monotherapy group (n=60, PPI alone). The two groups were compared before and after treatment in terms of the Reflux Symptom Index (RSI) score, Reflux Finding Score (RFS), 24-hour pharyngeal pH monitoring indicators, treatment efficacy, and the incidence of adverse events. Univariate and multivariate logistic regression analyses were conducted to identify factors influencing prognosis.
resultsAfter treatment, the combination group showed significantly lower RSI and RFS scores, lower Ryan score, number of reflux episodes, and percentage of reflux time than the monotherapy group (
conclusionsPPIs combined with gastroprokinetic agents are more effective than PPIs alone for patients with LPRD. This combination therapy alleviates patients' symptoms and improves their signs. Disease duration, BMI, hiatal hernia, smoking history, and treatment regimen are important factors influencing prognosis. Comprehensive interventions may improve patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.